Alastair James Morton

Alastair James Morton

Auto-generated profile, based on publicly available information

Alastair James Morton

School of Medicine, University of Nottingham, Nottingham, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2023 in British Journal of General Practice
Verified
Journal Article
Open access
PDF file
JBJames A Bailey
James A Bailey
AMAlastair J Morton
Alastair J Morton
JJJames Jones
James Jones
CCCaroline J Chapman
Caroline J Chapman
SOSimon Oliver
Simon Oliver
DHDavid J Humes
David J Humes
Background: Faecal immunochemical test (FIT) usage for symptomatic patients is increasing, but variations in use caused by sociodemographic factors are unknown. A clinical pathway for colorectal cancer (CRC) was introduced in primary care for symptomatic patients in November 2017. The pathway was commissioned to provide GPs with direct access to FITs.Aim: To identify whether sociodemographic factors affect FIT return in symptomatic patients.Design and setting: A retrospective study was undertaken in Nottingham, UK, following the introduction of FIT as triage tool in primary care. It was mandated for all colorectal referrals (except rectal bleeding or mass) to secondary care. FIT was used, alongside full blood count and ferritin, to stratify CRC risk.Method: All referrals from November 2017 to December 2021 were retrospectively reviewed. Sociodemographic factors affecting FIT return were analysed by multivariate logistic regression.Results: A total of 35 289 (90.7%) patients returned their index FIT, while 3631 (9.3%) did not. On multivariate analysis, males were less likely to return an FIT (odds ratio [OR] 1.11, 95% confidence interval [CI] = 1.03 to 1.19). Patients aged ≥65 years were more likely to return an FIT (OR 0.78 for non-return, 95% CI = 0.72 to 0.83). Unreturned FIT more than doubled in the most compared with the least deprived quintile (OR 2.20, 95% CI = 1.99 to 2.43). Patients from Asian (OR 1.82, 95% CI = 1.58 to 2.10), Black (OR 1.21, 95% CI = 0.98 to 1.49), and mixed or other ethnic groups (OR 1.29, 95% CI = 1.05 to 1.59) were more likely to not return an FIT compared with patients from a White ethnic group. A total of 599 (1.5%) CRCs were detected; 561 in those who returned a first FIT request.Conclusion: FIT return in those suspected of having CRC varied by sex, age, ethnic group, and socioeconomic deprivation. Strategies to mitigate effects on FIT return and CRC detection should be considered as FIT usage expands.

11 December 2023 in Techniques in Coloproctology
Verified
Journal Article
Open access
PDF file
AMA. J. Morton
A. J. Morton
ASA. Simpson
A. Simpson
DHD. J. Humes
D. J. Humes
Background: Laparoscopic and now robotic colorectal surgery has rapidly increased in prevalence; however, little is known about how uptake varies by region and sociodemographics. The aim of this study was to quantify the uptake of minimally invasive colorectal surgery (MIS) over time and variations by region, sociodemographics and ethnicity. Methods: Retrospective analysis of routinely collected healthcare data (Clinical Practice Research Datalink linked to Hospital Episode Statistics) for all adults having elective colorectal resectional surgery in England from 1 January 2006 to 31 March 2020. Sociodemographics between modalities were compared and the association between sociodemographic factors, region and year on MIS was compared in multivariate logistic regression analysis. Results: A total of 93,735 patients were included: 52,098 open, 40,622 laparoscopic and 1015 robotic cases. Laparoscopic surgery surpassed open in 2015 but has plateaued; robotic surgery has rapidly increased since 2017, representing 3.2% of cases in 2019. Absolute differences up to 20% in MIS exist between regions, OR 1.77 (95% CI 1.68–1.86) in South Central and OR 0.75 (95% CI 0.72–0.79) in the North West compared to the largest region (West Midlands). MIS was less common in the most compared to least deprived (14.6% of MIS in the most deprived, 24.8% in the least, OR 0.85 95% CI 0.81–0.89), with a greater difference in robotic surgery (13.4% vs 30.5% respectively). Female gender, younger age, less comorbidity, Asian or ‘Other/Mixed’ ethnicity and cancer indication were all associated with increased MIS. Conclusions: MIS has increased over time, with significant regional and socioeconomic variations. With rapid increases in robotic surgery, national strategies for procurement, implementation, equitable distribution and training must be created to avoid worsening health inequalities.

3 October 2022 in Anz Journal of Surgery
Verified
Journal Article
Open access
AMAlastair J. Morton
Alastair J. Morton
ARAdil Rashid
Adil Rashid
JSJoanna S. C. Shim
Joanna S. C. Shim
JWJoe West
Joe West
DHDavid J. Humes
David J. Humes
MGMatthew J. Grainge
Matthew J. Grainge
Background: As rectal cancer survival increases, more patients survive with potentially severe, long‐term gastrointestinal and genitourinary complications from radiotherapy. The burden of these complications for patients and healthcare services is unclear, which this review aims to quantify.Methods: Systematic search of Medline and Embase for randomized‐controlled trials (RCTs) and multicentre observational studies published since 2000, reporting hospitalization/procedural intervention for long‐term (>6 months post‐treatment) gastrointestinal or genitourinary complications after radiotherapy and surgery for rectal cancer. Prevalence values were pooled in a meta‐analysis assuming random effects. Organ‐preservation patients were excluded.Results: 4044 records screened; 24 reports from 23 studies included (15 RCTs, 8 Observational), encompassing 15 438 patients. Twenty‐one studies (median follow‐up 60 months) reported gastrointestinal complications post‐radiotherapy: pooled prevalence 11% (95% confidence interval (95% CI) 8–14%). Thirteen reported small bowel obstruction: prevalence 9% (95% CI 6–12%), a 58% increased risk compared with surgery alone (RR 1.58, 95% CI 1.26–1.98, n = 5 studies). Seven reported fistulas: prevalence 1% (95% CI 1–2%). Thirteen reported genitourinary complications: prevalence 4% (95% CI 1–6%); RR 1.10 (95% CI 0.88–1.38, n = 3 studies) compared with surgery alone.Conclusions: Over 10% of patients are hospitalized for long‐term complications following rectal cancer radiotherapy. Serious gastrointestinal complications are commonplace; late small bowel obstruction is more common in patients having radiotherapy and surgery compared with surgery alone. Patients and clinicians need to be aware of these risks.

3 January 2024 in Colorectal Disease
Verified
Journal Article
Open access
JBJ. A. Bailey
J. A. Bailey
AMA. J. Morton
A. J. Morton
JJJ. Jones
J. Jones
CCC. J. Chapman
C. J. Chapman
SOS. Oliver
S. Oliver
ABA. Banerjea
A. Banerjea
Aim: The aim of this work was to evaluate colorectal cancer (CRC) outcomes after ‘low’ (sub‐threshold) faecal immunochemical test (FIT) results in symptomatic patients tested in primary care.Method: This work comprised a retrospective audit of 35 289 patients with FIT results who had consulted their general practitioner with lower gastrointestinal symptoms and had subsequent CRC diagnoses.The Rapid Colorectal Cancer Diagnosis pathway was introduced in November 2017 to allow incorporation of FIT into clinical practice. The local ‘4F’ protocol combined FIT results with blood tests and digital rectal examination (DRE): FIT, full blood count, ferritin and finger [DRE]. The outcome used was detection rates of CRC, missed CRC and time to diagnosis in local 4F protocols for patients with a subthreshold faecal haemoglobin (fHb) result compared with thresholds of 10 and 20 μg Hb/g faeces.Results: A single threshold of 10 μg Hb/g faeces identifies a population in whom the risk of CRC is 0.2%, but this would have missed 63 (10.5%) of 599 CRCs in this population. The Nottingham 4F protocol would have missed fewer CRCs [42 of 599 (7%)] despite using a threshold of 20 μg Hb/g faeces for patients with normal blood tests. Subthreshold FIT results in patients subsequently diagnosed with a palpable rectal tumour yielded the longest delays in diagnosis.Conclusion: A combination of FIT with blood results and DRE (the 4F protocol) reduced the risk of missed or delayed diagnosis. Further studies on the impact of such protocols on the diagnostic accuracy of FIT are expected. The value of adding blood tests to FIT may be restricted to specific parts of the fHb results spectrum.

20 August 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
FMFrancesca Ligori Malcolm
Francesca Ligori Malcolm
AYAnjali K. D. S. Yapa
Anjali K. D. S. Yapa
ZWZhen Yu Wong
Zhen Yu Wong
AMAlastair James Morton
Alastair James Morton
CCColin Crooks
Colin Crooks
DHDavid Humes
David Humes
Summary: Background: Faecal haemoglobin (f‐Hb) testing is used in colorectal cancer (CRC) screening and increasingly to guide the investigation in patients with symptoms suggestive of CRC. Studies have demonstrated increased mortality with raised f‐Hb.Aims: To assess the association of raised f‐Hb with all‐cause, non‐CRC (any cause excluding CRC) and cause‐specific mortality.Methods: We searched Medline and Embase on 9 February 2024 to identify papers reporting mortality after faecal immunochemical (FIT) or guaiac faecal occult blood tests (gFOBT). The primary outcome was all‐cause mortality following a positive compared to a negative test.Results: The search identified 3155 papers. Ten met the inclusion criteria: three reported gFOBT and seven reported FIT results, as screening tests. These reported a total of 14,687,625 f‐Hb results. Elevated f‐Hb was associated with an increased risk of all‐cause, non‐CRC and cause‐specific mortality including death from cardiovascular, digestive and respiratory diseases. Crude risk ratios for all‐cause mortality with a positive versus negative test were derived from six papers (three reporting gFOBT, three FIT). An increased risk was demonstrated in five, with RRs ranging from 1.11 (95% CI: 1.06–1.16) to 2.95 (95% CI: 2.85–3.05). For non‐CRC mortality risk, RRs ranged from 1.09 (95% CI: 1.04–1.15) to 2.79 (95% CI: 2.70–2.89). We did not perform meta‐analysis due to a limited number of papers reporting suitable results for each type of f‐Hb test.Conclusions: All‐cause, non‐CRC and cause‐specific mortality appear higher in those with raised f‐Hb. Population‐based studies are warranted to elicit whether this association occurs in symptomatic patients.

1 June 2025 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
AMAlastair James Morton
Alastair James Morton
CCColin J Crooks
Colin J Crooks
JWJoe West
Joe West
BNBrian David Nicholson
Brian David Nicholson
DHDavid J Humes
David J Humes
Background/Objectives: Faecal Immunochemical Testing (FIT) is recommended for patients presenting to primary care with symptoms suggestive of colorectal cancer. This study quantified variations in use across England. Methods: Retrospective cohort of English patients (≥ 18 years) with a FIT result reported in routinely collected primary care records, 2019– 2023. Rates of FIT testing by age, sex, year and region were adjusted using Poisson regression. Multivariate logistic regression compared the effect of factors on the proportion of results exceeding the recommended referral threshold (10μgHb/g). Results: Between 01/01/2019 and 05/06/2023 there were 531,735 FIT results among 495,121 patients. Rates of testing increased from 0.69 per thousand person-years in 2019 (95% CI 0.68– 0.71) to 27.70 in 2023 (95% CI 27.56– 27.85). There were large variations in testing between regions, with rates > 3-fold higher in the Northeast than the West Midlands: 17.05 (95% CI 16.87– 17.23) versus 4.72 (95% CI 4.67– 4.76) per thousand person-years. About 20.4% of FIT results were ≥ 10μgHb/g. Despite increased testing, this did not change over time. The proportion of FIT ≥ 10μgHb/g was lower in regions with higher rates of testing, from 16.7% (Southwest) to 25.3% (Southeast; rates of testing 14.62 and 8.00 per thousand person-years respectively). This difference in proportion of FIT ≥ 10μgHb/g persisted after adjusting for year, sex and age (OR 0.57, 95% CI 0.55– 0.58). Conclusion: Rapid increases in FIT testing in primary care show large, persistent variations between English regions, which correlate with the proportion of results meeting the criteria for onward referral. Differences in the population tested and FIT’s implementation between regions are likely to explain these variations. Plain Language Summary: 1) Why was this study done?A simple test for blood in the poo, called FIT, can help decide whether a person with bowel symptoms seeing their primary care doctor should be referred to a hospital for further bowel investigations.Currently, a FIT result of 10 μgHb/g faeces or more is recommended to guide referral for bowel tests.No study has reported how FIT use, or results, differs across England. 2) What did the researchers find?This is the first study on national patterns of FIT testing, showing a rapid but unequal increase across England.There is large variation in the proportion of FIT results exceeding the referral criteria of 10 μgHb/g faeces between English regions that is associated with the rate of testing in each region. 3) What do these results mean?Using a single FIT value as a threshold for onwards referral may work differently in different regions of England. As FIT is adopted more widely and rates of testing increase, primary care services may see a decrease in the proportion of patients with a FIT result reported over the referral threshold.